Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

For men with intermediate or high-risk prostate cancer, can an SBRT boost be used in place of a brachytherapy boost after EBRT?

7
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Oakland University William Beaumont School of Medicine

I would respectfully disagree with @Dr. First Last and @Dr. First Last on this subject. Probably because the issue is much more complicated than they elude.One thing that is not complicated is that dose is dose. Or rather effective dose is effective dose. So any method of accurately delivering that ...

Is it appropriate to re-consider bladder preservation in patients with bladder muscle-invasive cancer (T2) who were initially poor candidates for BP (multifocal disease, etc.) but had complete response after neoadjuvant chemotherapy?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Harvard Medical School

It is perfectly appropriate. There are many ways to achieve a complete response to T2 bladder cancer. It can be reached with radiation, an aggressive local resection, or chemotherapy. The issue is whether or not it is durable. None of these therapies alone have a great track record, although chemoth...

Do you use different dose constraints for large bowel vs. small bowel?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of North Carolina at Chapel Hill

I am not going to exactly answer this question, but rather give some thoughts on the issue of bowel tolerance. I think we need to be careful in just plugging in numerical constraints but need to consider the question more broadly. There are good data to show that small volumes of rectum can tolerate...

Do you recommend neoadjuvant and concurrent ADT vs concurrent ADT for salvage post prostatectomy radiation?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cancer Specialists of North Florida

I do both neoadjuvant and concurrent. The strategy used is typically dictated by patient schedule/convenience.While GETUG-AFU 16 used a concurrent approach, SPPORT utilized a 2-month neoadjuvant strategy for ADT.

In patients with skin squamous cell carcinoma invading the skull, what dose do you limit the brain when treating definitively with radiation?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Vanderbilt-Ingram Cancer Center

Brain (excluding optic structures and brain stem) can handle all sorts of doses to limited volumes. I would just try to avoid dumping hotspots < 105-110% of your Rx dose into the brain and try to minimize the Rx dose, which will be dependent on anatomy and the extent of abutment/overlap of PTV with ...

How do you treat severe vaginal stenosis after radiation in a patient that is already compliant with dilators?

1
2 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Medical University of South Carolina

Local estrogen helps a lot. Compliance can be a problem. I suggest that the patient will cover their applicator with estrogen and insert after she goes to bed at night and just leave it in. It will usually come out during the night but this usually beats the patient having to take time out during th...

Do you routinely prescribe memantine for patients who will be receiving hippocampal sparing whole brain RT if they are already on donepezil, or is donepezil alone sufficient?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · West Virginia University

I typically prescribe memantine along with WBI and H/A. Not sure there ever was a study comparing the WBI component (with HA) with or without memantine. Maybe that study would show that the HA technique is the major benefit and the drug does very little. Lots of patients are on both memantine and Ar...

Should inoperable squamous cell carcinoma of the esophagus be treated to doses > 60 Gy?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of North Carolina at Chapel Hill

The article mentioned does not, in my opinion, provide sufficient evidence to justify a change in clinical practice. As a general rule, I think we should be extremely careful about using data from retrospective data reviews, such as this review or the commonly used NCDB database, to assert that one ...

In asymptomatic patients with castrate resistant prostate cancer who have failed chemotherapy and have progressive vertebral body metastases, when do you prescribe lutetium-177 vs prophylactic spinal radiation?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Goals are different. Pluvicto is administered to improve pain, PFS, OS, and quality of life so it is SOC for patients who fail chemotherapy and have PSMA avid disease while good prophylactic RT is to prevent local bone-related events only.

For patients with large, partially or nearly obstructing rectal cancers, how do you sequence TNT in order to avoid complete obstruction and surgical diversion?

4
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of North Carolina at Chapel Hill

I personally favor starting with RT/chemo, but starting with chemo can work well. The more important issue is the side questions. First, there is a huge difference between a lesion that is large and one that is nearly completely obstructing. Unfortunately, many endoscopists use the term "obstructing...